How to talk to your doctor about peptides (questions and a script)

Why it is worth raising

If you are using a peptide, or thinking about it, your doctor is the person best placed to spot problems you cannot see yourself: an interaction with another medicine, a blood test that has drifted, or a symptom that points to something else. That only works if they know. Yet many people hold back. A 2026 study of online health information found that patients frequently search online and value a doctor's help interpreting what they find, but many hesitate to share their searches during consultations (survey study) ¹.

People who use performance or image-enhancing substances hold back most. A review of anabolic steroid users found they tended to prefer peer advice and online forums over professionals, reflecting the stigma they experience, and that this acts as a barrier to services (scoping review) ². The cost can be real: in one study of men with current steroid use, 44% of those with reduced heart pumping function had never sought health care for side effects (cross-sectional study) ³. Peptides are not steroids, but the reluctance and the risk of missing problems are similar.

Doctors hear this more than you think

Bringing up something you saw online is routine. In a 2026 survey of 1,889 Australian general practitioners, 59.2% said patients raise health information from social media in consultations every week, most often about medication (72.0%) and diagnoses (56.5%) (survey of doctors) ⁴. Most of those GPs said such requests are rarely or never supported by scientific evidence and that they rarely fulfil them, yet nearly half said social media had no effect on the doctor-patient relationship ⁴. In other words, doctors are used to the conversation; what they need is accurate information about what you are actually taking.

What your doctor is likely to worry about

Knowing the concerns in advance makes the conversation easier, because you can bring the answers.

• What is really in the vial. Research peptides are not made or tested as medicines for people; studies of products bought online have found wrong amounts and contamination. A 2024 study of semaglutide bought without a prescription found overdosed vials, with endotoxin in every one tested (test purchase) ⁵. FDA lists several peptides, including some sold online, among bulk substances that may pose significant safety risks in compounding ⁶.
• Interactions. Approved peptides carry label warnings that depend on your other medicines. The Wegovy and Mounjaro labels warn that combining them with insulin or sulfonylureas raises the risk of low blood sugar, and Wegovy's label advises against using it with any other semaglutide product or GLP-1 drug ⁷. Our blood sugar guide explains why.
• Evidence. Most research peptides have little or no human evidence; the encyclopedia grade for each tells you where it stands.
• Sport and work rules. If you are a tested athlete, many peptides are prohibited; our WADA hub lists them.

What to bring

A short, organised list helps more than a stack of printouts. The table summarises what is most useful.

Our encyclopedia gives each peptide an evidence grade and dated regulatory status with sources, which can be a neutral starting point; our Approved-Alternative Finder lists approved medicines for common goals, with each label's own indication.

Checks a doctor may suggest

For approved peptides, the labels themselves name the checks that matter, and they are a reasonable guide to what a doctor may want for related research products too. The EGRIFTA WR label for tesamorelin warns that glucose intolerance or diabetes may develop and advises evaluating glucose before and during treatment ⁸. The INCRELEX label for IGF-1 warns of severe low blood sugar and advises glucose monitoring while the dose is adjusted ⁹. The Vyleesi label for bremelanotide asks prescribers to consider cardiovascular risk and blood pressure before starting, because each dose briefly raises blood pressure ¹⁰.

So depending on what you take, a doctor may suggest a fasting glucose or HbA1c test, a blood pressure check, liver tests, or a look at an injection site. Asking 'what would you check, given what I'm taking?' turns the appointment from a yes-or-no verdict into a plan.

Keep a simple record

A one-page record makes every appointment easier: the product name and batch, where it came from, start date, amount and schedule, any changes, and any symptoms with dates. Keep the label or a photo of it, and any certificate that came with it. If you stop, note the date. This helps a doctor link a symptom to a product, helps a pharmacist check interactions, and is invaluable in an emergency, when you may not be able to explain. It also helps regulators: reports of harm from specific batches are how problems are found, as the 2026 alerts on products labelled retatrutide showed, which our retatrutide testing article describes.

A script you can use

You do not need to justify yourself. A calm, factual opening works best. Adapt this to your situation:

'I want to be upfront about something. I've been using [peptide name], which I bought [online / from a clinic], for [how long], at [how much, how often]. I brought the label [and the certificate]. I'm using it because I want [goal]. I'd like your honest view on what's known about it, whether it could interact with anything I take, whether I should have any tests, and whether there's an approved option that does the same job.'

If you have not started yet:

'I've been reading about [peptide name] for [goal]. Before I do anything, I'd like to know what the evidence shows, whether it's safe with my other medicines, and what you'd suggest instead.'

If something has gone wrong, lead with the symptom and the timing, then the product: 'For the past [time] I've had [symptom]. It started after I began injecting [peptide name]. Here is the vial.' Our guide to injection-site reactions lists signs that need prompt care.

Questions to ask

• What does the evidence actually show for this peptide, in people?
• Could it interact with anything else I take?
• Should I have any baseline or follow-up tests, such as blood sugar, liver function or blood pressure?
• Is there an approved medicine for the same goal, and would I qualify for it?
• What symptoms should make me stop and contact you?
• If I decide to continue, can you keep an eye on me?

If the conversation goes badly

Some doctors will be blunt, and some may simply say no. That is their professional judgement, and it is often based on the same evidence gaps our encyclopedia records. It is reasonable to ask what would change their view, to ask for the specific concern in writing in your notes, or to seek a second opinion from a doctor with relevant expertise, such as an endocrinologist for growth hormone or metabolic peptides. It is not a reason to stop telling clinicians what you take: the next doctor, the pharmacist or an emergency team may need to know.

Be wary of the opposite reaction too. A clinic that sells peptides alongside its advice has a stake in the answer; UK regulators investigated peptide clinics in 2026 over medicinal claims for unlicensed products, as our UK country page describes.

If the prescriber is a telehealth service or peptide clinic

Some people get peptides through online services or clinics rather than their usual doctor. The same questions apply, with a few more: is the product an approved medicine, a compounded preparation, or something else; which pharmacy makes it; and does the prescriber know your full history and other medicines? FDA's compounding lists record which bulk peptides pharmacies may and may not use, and several popular peptides sit on its list of substances that may present significant safety risks ⁶. Our guide to compounded, branded and research tirzepatide explains why those categories differ. Whoever prescribes, make sure your usual doctor knows too, so one person sees the whole picture.

Being honest about the evidence yourself

The conversation goes better when you go in with an accurate picture. If a peptide's evidence is mostly in rats, say so; if it is an approved drug used off-label, say that. Our guides to reading a peptide study and to what 'research use only' means can help you separate marketing from evidence before the appointment. A doctor who sees you have weighed the evidence is more likely to engage with your goal than to dismiss the question.

The bottom line

Doctors hear about online health trends every week, so raising peptides is ordinary. Telling them protects you: interactions, quality problems and side effects are easier to catch when they know. Bring the product, your medicine list, dates and goals; ask what is known, what is approved for the same goal, and what to monitor; and keep every clinician informed even if the first conversation does not go the way you hoped.

Frequently asked questions

Should I tell my doctor I am using peptides?

Yes. Peptides can interact with other medicines and research products have known quality problems; your doctor can only watch for these if they know what you take.

What should I bring to the appointment?

The product or a photo of its label and any certificate, how much and how often you take it and since when, every other medicine and supplement, any symptoms, and your goal.

Will my doctor judge me?

Doctors routinely hear about health information from social media; in one survey most GPs said patients raise it weekly. Being factual and open usually leads to a more useful conversation.

What if my doctor says no?

Ask what the specific concern is and what would change their view, and consider a second opinion from a relevant specialist. Keep telling clinicians what you take.

Can my doctor prescribe peptides?

Doctors can prescribe approved peptide medicines for their labelled uses. Most research peptides are not approved, and our Approved-Alternative Finder lists approved options for common goals.

Related on Grey Peptides

• Approved-Alternative Finder
• Injection-site reactions
• Peptides and blood sugar

Sources

1. Lu, Q., et al. (2026). Seeking But Not Discussing Online Health Information With Physicians: Cross-Sectional Survey Study of eHealth Literacy-Empowerment Profiles and Patient-Centered Communication. J Med Internet Res, 28, e78836. PMID: 41707191
2. Harvey, O., et al. (2019). Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access. BMC Public Health, 19(1), 1024. PMID: 31366349
3. Henriksen, H. C. B., et al. (2024). Treatment-seeking behavior and cardiovascular morbidity among men with anabolic-androgenic steroid use: A cross-sectional study. Scand J Med Sci Sports, 34(1), e14554. PMID: 38268076
4. Nickel, B., et al. (2026). The impact of social media health information on general practice consultations in Australia: A cross-sectional study of general practitioners. Aust J Gen Pract, 55(6), 360-364. PMID: 42242303
5. Ashraf, A. R., et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res, 26, e65440. PMID: 39509151
6. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026; read October 1, 2026. FDA
7. WEGOVY (semaglutide) prescribing information, Limitations of Use and Warnings 5.4 (DailyMed version 19, effective June 18, 2026), and MOUNJARO (tirzepatide) prescribing information, Warnings 5.3 (DailyMed version 40, effective August 27, 2026); read October 1-3, 2026.
8. Theratechnologies. EGRIFTA WR (tesamorelin) US prescribing information, Warnings and Precautions 5.4. DailyMed version 2, effective July 29, 2026; read October 1, 2026.
9. Eton Pharmaceuticals. INCRELEX (mecasermin) US prescribing information, Warnings and Precautions 5.1 (Hypoglycemia). DailyMed version 5, effective May 18, 2026; read October 1, 2026.
10. VYLEESI (bremelanotide injection) US prescribing information, Warnings and Precautions 5.1. DailyMed version 1, effective November 13, 2025; read October 1, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.